Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference
September 06 2022 - 4:05PM
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to
transforming the lives of those affected by cancer and other
serious diseases, today announced participation in the H.C.
Wainwright 24th Annual Global Investment Conference. An on-demand
webcast of the presentation will be available on Monday, September
12, 2022, at 7 a.m. ET.
The webcast will be available on
the Investors and Media section of the Kronos Bio website
at www.kronosbio.com. A replay of the webcast will be archived
and available for 30 days following the event.
About Kronos Bio, Inc.Kronos
Bio is a biopharmaceutical company that is advancing three
investigational compounds in clinical trials for patients with
cancer. The company’s lead compound, the SYK inhibitor
entospletinib, is being evaluated in the registrational Phase 3
AGILITY trial as a treatment for patients with newly diagnosed
NPM1-mutated acute myeloid leukemia (AML). The company is also
developing the CDK9 inhibitor, KB-0742, as a treatment for
MYC-amplified solid tumors and lanraplenib, a next-generation SYK
inhibitor being assessed in patients with FLT3-mutated AML. The
company’s scientific focus is on developing medicines that target
the dysregulated transcription that is the hallmark of cancer and
other serious diseases.
Kronos Bio is based in San Mateo, Calif., and
has a research facility in Cambridge, Mass. For more information,
visit www.kronosbio.com or follow the company on LinkedIn.
Company Contact:Marni
KottleKronos Bio 650-900-3450mkottle@kronosbio.com
Investors:Claudia StyslingerArgot
Partners212-600-1902kronosbio@argotpartners.com
Media:Sheryl SeapyReal
Chemistry949-903-4750sseapy@realchemistry.com
Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Jul 2023 to Jul 2024